Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bausch & Lomb Corp (BLCO)

Bausch & Lomb Corp (BLCO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,053,432
  • Shares Outstanding, K 354,209
  • Annual Sales, $ 4,791 M
  • Annual Income, $ -317,000 K
  • EBIT $ 358 M
  • EBITDA $ 814 M
  • 60-Month Beta 0.61
  • Price/Sales 1.21
  • Price/Cash Flow 9.16
  • Price/Book 0.93
  • Price/Earnings ttm 39.91
  • Earnings Per Share ttm 0.43
  • Most Recent Earnings $0.18 on 10/29/25
  • Next Earnings Date 02/18/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING:

    SIC-3851 Ophthalmic Goods

    Medical Services

Options Overview Details

View History
  • Implied Volatility 50.95% (-105.45%)
  • Historical Volatility 19.59%
  • IV Percentile 33%
  • IV Rank 11.26%
  • IV High 187.31% on 11/19/25
  • IV Low 33.65% on 01/31/25
  • Expected Move (DTE 30) 1.02 (5.91%)
  • Put/Call Vol Ratio 0.06
  • Today's Volume 178
  • Volume Avg (30-Day) 218
  • Put/Call OI Ratio 0.20
  • Today's Open Interest 2,721
  • Open Int (30-Day) 2,823
  • Expected Range 16.24 to 18.28

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.35
  • Number of Estimates 6
  • High Estimate 0.39
  • Low Estimate 0.31
  • Prior Year 0.25
  • Growth Rate Est. (year over year) +40.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.22 +6.41%
on 01/05/26
17.86 -3.36%
on 01/13/26
+0.28 (+1.65%)
since 12/19/25
3-Month
14.44 +19.53%
on 11/20/25
17.86 -3.36%
on 01/13/26
+1.63 (+10.43%)
since 10/21/25
52-Week
10.45 +65.17%
on 04/30/25
18.14 -4.85%
on 01/30/25
+0.08 (+0.47%)
since 01/21/25

Most Recent Stories

More News
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2025 Financial Results on Feb. 18

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2025 financial results...

BLCO.TO : 23.84 (+1.15%)
BLCO : 17.26 (+0.99%)
Bausch + Lomb Partners with Glaucoma Research Foundation and The Glaucoma Foundation to Address a Leading Cause of Irreversible Blindness in the U.S.

Bausch + Lomb to launch fifth annual fundraising challenge during Glaucoma Awareness Month in partnership with Glaucoma Research Foundation, with all proceeds supporting glaucoma research ...

BLCO.TO : 23.84 (+1.15%)
BLCO : 17.26 (+0.99%)
Bausch + Lomb Completes Refinancing of Outstanding Term B Loans

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “company”), a leading global eye health company dedicated to helping people see better to live better, today announced that it...

BLCO.TO : 23.84 (+1.15%)
BLCO : 17.26 (+0.99%)
Bausch + Lomb to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders, Executive Vice...

BLCO.TO : 23.84 (+1.15%)
BLCO : 17.26 (+0.99%)
1 Profitable Stock to Keep an Eye On and 2 We Question

1 Profitable Stock to Keep an Eye On and 2 We Question

PNTG : 30.00 (+2.39%)
VEEV : 219.73 (+1.60%)
BLCO : 17.26 (+0.99%)
Bausch + Lomb Announces Two Board of Directors Appointments

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Eduardo C. Alfonso, MD, and Steven H. Collis...

BLCO.TO : 23.84 (+1.15%)
BLCO : 17.26 (+0.99%)
Bausch + Lomb Announces Refinancing of Outstanding Term B Loans

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “company”), a leading global eye health company dedicated to helping people see better to live better, today announced that it...

BLCO.TO : 23.84 (+1.15%)
BLCO : 17.26 (+0.99%)
Why Bausch + Lomb (BLCO) Stock Is Trading Up Today

Why Bausch + Lomb (BLCO) Stock Is Trading Up Today

BLCO : 17.26 (+0.99%)
3 Healthcare Stocks We Think Twice About

3 Healthcare Stocks We Think Twice About

EVH : 3.80 (-3.55%)
BLCO : 17.26 (+0.99%)
BIIB : 172.62 (+4.38%)
Why Bausch + Lomb (BLCO) Stock Is Up Today

Why Bausch + Lomb (BLCO) Stock Is Up Today

BLCO : 17.26 (+0.99%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Bausch Lomb Corporation is an eye health company. Its product portfolio includes Biotrue(R) and renu(R) multi-purpose solutions, Biotrue(R) ONEday daily disposable contact lenses, LUMIFY(R) redness reliever eye drops, PreserVision(R) AREDS 2 formula eye vitamin and mineral supplements and VYZULTA(R)....

See More

Key Turning Points

3rd Resistance Point 17.80
2nd Resistance Point 17.61
1st Resistance Point 17.44
Last Price 17.26
1st Support Level 17.07
2nd Support Level 16.88
3rd Support Level 16.71

See More

52-Week High 18.14
Last Price 17.26
Fibonacci 61.8% 15.20
Fibonacci 50% 14.30
Fibonacci 38.2% 13.39
52-Week Low 10.45

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar